The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Giredestrant Improves Breast Cancer Survival Regardless of Menopause
Giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved invasive disease-free survival in early breast cancer.
Prostatic NeoplasmsAlpha-Emitting Radioantibody Lowers PSA in CRPC
An investigational alpha-emitting radioantibody demonstrated a reduction in PSA levels in patients with castration-resistant prostate cancer (CRPC).
Breast NeoplasmsGenetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy
A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.
Half of Older Adults With Metastatic Lung Cancer Receive No Systemic Treatment
8 min readTucatinib Extends PFS in HER2-Positive Breast Cancer, No New Safety Signals
11 min readBiomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
9 min readWearable Devices Detect CAR-T CRS Hours Earlier, Improving Patient Outcomes
7 min readBowhead Whale Longevity Genes Offer Clues for Cancer, Aging
8 min read
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
Portal HypertensionVariceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.
CholestasisNearly 1 in 10 With Primary Biliary Cholangitis Have CKD
Chronic kidney disease affects 9.5% of patients with primary biliary cholangitis, with hypertension and older age driving incidence.
EASL 2026 Forum: Enhancing Patient-Clinician Communication
8 min readMetabolic Dysfunction Associated Steatotic Liver Disease: An Overview
5 min readLiver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
7 min readEASL 2026: Alcohol Policy Action Needed for Liver Disease
7 min read
ESC Cardio-Oncology 2026: Key Sessions and Anticipated Focus Areas
The ESC Cardio-Oncology 2026 congress will address cardiotoxicity from cancer therapies, focusing on early detection and management strategies.
Coronary Artery DiseaseNovel Therapies Target Atherogenic Lp(a) Particle
Emerging therapeutic strategies are shifting focus from LDL cholesterol to apoB, targeting Lp(a) and other atherogenic particles.
Congenital Heart Defects5D MRI Halves Scan Time for Congenital Heart Disease Imaging
A novel 5D MRI technique significantly reduces scan duration for congenital heart disease patients, improving image quality and patient experience.
Heat-Attributable CVD Years of Life Lost Projected to Rise Through 2050
8 min readUniversal Heart Failure Definition Issued by Global Societies
10 min readAI-Assisted Fetal Echocardiography Improves Early CHD Detection
8 min readHypotension Linked to Increased Alzheimer's Disease Risk
7 min readClopidogrel and Omeprazole: Re-evaluating Concomitant Use Risk
7 min read
Unapproved Retatrutide Use Challenges Clinicians
The off-label use of investigational retatrutide for weight management presents a significant challenge for clinicians, lacking robust long-term safety and efficacy data.
Diabetes Mellitus Type 2Elecoglipron Oral GLP-1 Reduces Glucose, Weight in Phase 2
Elecoglipron, an investigational oral GLP-1 receptor agonist, demonstrated reductions in HbA1c and body weight in phase 2 trials.
Diabetes Mellitus Type 2GLP-1 Receptor Agonist Use Varies Widely for Youth Type 2 Diabetes
Geographic variation in GLP-1 receptor agonist prescribing for youths with type 2 diabetes across the US highlights disparities in care.
GLP-1s for Addiction: Are We There Yet?
10 min readGLP-1 Agonists Show Ocular Safety, Potential Therapeutic Role
9 min readMedically Tailored Meals Cut HbA1c More Than Subsidies in Type 2 Diabetes
11 min readIsaacs Emphasizes 'Human Touch' in Diabetes Care Beyond Technology
9 min readGLP-1 Nonresponders Often Underserved by Inadequate Dosing, Poor Adherence
10 min read
TBI Linked Bidirectionally With Psychiatric and Neurologic Conditions
Traumatic brain injury (TBI) shows a two-way association with various psychiatric and neurologic conditions, increasing risk for both and being influenced by their presence.
Migraine DisordersMigraine Linked to Increased Vascular Dementia Odds in Observational Data
Observational studies indicate a consistent association between a history of migraine and elevated odds for developing vascular dementia later in life.
Amyotrophic Lateral SclerosisHuntington's Disease Therapy Faces Regulatory Setbacks, Clinical Impact
A novel investigational therapy for Huntington's disease has encountered significant regulatory hurdles, prompting re-evaluation of its clinical development pathway.
Dopamine Agonists: A Fading Role in Parkinson's Treatment?
9 min readEptinezumab Improves Cognitive Symptoms in Migraine Patients
13 min readNew Parkinson's Drug Offers Sustained Levodopa Levels
9 min readCreatine Supplementation: Limited Evidence for Brain Health Benefits
11 min readML Model Predicts Epilepsy Onset in Depression, Depression in Epilepsy
9 min readNew Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
7 min readFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
8 min readMonoclonal Antibodies May Complicate Transfusion Testing
7 min readBlood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections
7 min readChemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
8 min readPersonalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
7 min readMacrophages: Dual Role in Haematological Malignancies Explored
7 min readMolecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
7 min readITP Management: Bridging Clinician and Patient Perspectives
7 min readCLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
8 min read
Sleep Disruption and Fear Drive Chronic Rheumatic Pain
11 min readPodcast: Why Cheaper Humira Alternatives Face Resistance
ListenPodcast: Stopping Spinal Fusion Or Protecting The Gut?
ListenPodcast: Chasing Absolute Zero In Rheumatoid Arthritis
ListenPodcast: The ORAL Surveillance JAK Inhibitor Controversy
Listen
Air Embolism: Two Cases After Percutaneous Lung Biopsy
7 min readSingle Question May Flag Poor Quality Sleep in Patients
9 min readPembrolizumab Reduces Pulmonary AEs vs Chemotherapy in NSCLC
8 min readDupilumab Superior to Omalizumab in High-Biomarker Asthma
7 min readATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
8 min read
COVID Vaccine Efficacy in Children: A Review of Real-World Data
8 min readRifadin Syrup Under Review for Carcinogen Concerns
7 min readPublic Health Measures Significantly Reduced COVID-19 Incidence
8 min readData Integrity Concerns Raised in Pfizer's COVID-19 Vaccine Trial
7 min readVaccine Cold Chain Integrity Underpins Vaccine Security
8 min read
CAR T-Cell Therapy Nears Approval for Refractory Skin Diseases
7 min readTSW Controversy: Mitochondrial NAD Excess Identified, Diagnostic Clarity Emerges
9 min readPrior Authorization Delays Atopic Dermatitis Treatment Access
13 min readPatient-Reported Factors Redefine Alopecia Areata Severity
7 min readScalp Lesions: Rare Malignancies Mimic Benign Conditions
7 min readAlcohol and Sugar: A Dual Metabolic Challenge for Patients
Vitamin K2 Supplementation May Curb Coronary Calcification
Cognitive Rehabilitation Eases Long-COVID Brain Fog
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
7 min readCurrent and Emerging Therapies for Pulmonary Tuberculosis
6 min readDown Syndrome: Skin Conditions Demand Dermatologists’ Attention
7 min read
Munich, DEAug 28 – 31UpcomingEASD 2026
Madrid, ESSep 9 – 12UpcomingERS 2026
Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026
Vienna, ATOct 3 – 7UpcomingAHA 2026
Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026
Stockholm, SEJun 11 – 14PastEULAR 2026
London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30UpcomingESC 2026Munich, DEAug 28 – 31UpcomingEASD 2026Madrid, ESSep 9 – 12UpcomingERS 2026Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026Vienna, ATOct 3 – 7UpcomingAHA 2026Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026Stockholm, SEJun 11 – 14PastEULAR 2026London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
Caplacizumab Improves iTTP Outcomes in Real-World Settings
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
Early Breast Cancer at ASCO 2026: Trials to Watch
Pediatric Advanced Bronchoscopy: Precision in Airway Management
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
CLL First-Line Therapy: Case-Based Insights from EHA 2026
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
Multidisciplinary Care Improves Spondyloarthritis Outcomes
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
More Breast Cancer Patients Can Skip Axillary Dissection
Infection Prevention Critical in Hematological Malignancies
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
Sarcoidosis: Current Understanding of Diagnosis and Management
AI in Oncology: Practical Applications Transforming Cancer Care
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
ILD Diagnosis and Management: A Practical ATS 2026 Update
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
Inluriyo™ and Verzenio® Presentations at ASCO 2026
RA Care: Navigating Treatment Choices at EULAR 2026
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
Ventilator Management: Foundations for Bedside Implementation
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
XLH Management: Rheumatology Must Adapt at EULAR 2026
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
NDMM Treatment Optimisation: Communication Key to Individualisation
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
Obesity Management Improves Psoriatic Disease Outcomes
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
ICI Dissemination Challenges Highlighted at ASCO 2026
Infection Prevention Critical in Hematological Malignancies
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
Evolving Infection Prevention in HSCT and Cellular Therapies
CD20-Targeted Therapies Remain Central to NHL Management
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
Multidisciplinary Approach Improves Autoimmune ILD Management
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
Early Intervention in SLE/LN Reduces Long-Term Damage
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
Hypercortisolism: Emerging Diagnostic and Management Insights
Triple Therapy Optimises COPD Outcomes at ATS 2026
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
ASCO 2026: Anticipating Advances in Oncology Treatment
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
How Immunotherapy Unmasks Invisible Lung Cancer
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
EASL 2026: PSC Therapies Advance Beyond Symptom Management
Inflammation Drives Sickle Cell Disease Pathophysiology
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
RA Treatment Optimisation: Applying Two Decades of Progress
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
EULAR 2026: Psoriatic Disease Spectrum Highlights
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
Afirma Molecular Testing: Unique Situations and New Prognostic Development
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
AI Foundation Models Enhance Diagnostic Insights in Oncology
ITP Management: Bridging Clinician and Patient Perspectives
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
Pediatric Pulmonary Research Gaps Highlighted for Global Health
ATS 2026: Ultrasound Education Advances for Clinical Practice
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
Outsmarting Shape-Shifting Lung Cancer Resistance
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
New Biologic Offers Option for Severe Eosinophilic Asthma
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
CAR T: Speed and Reliability Critical for Patient Outcomes
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
Low Alkaline Phosphatase: Recognizing Clinical Consequences
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
Macrophages: Dual Role in Haematological Malignancies Explored
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
Novel Biomarkers Improve Pediatric Solid Tumor Detection
EHA 2026: Anticipating Advances in Haematological Malignancies
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
CML Survivorship: Beyond Survival to Quality of Life
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
Classic CAH: New Approaches to Glucocorticoid Dosing
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
Immunological Insights Inform ILD & Transplant Outcomes
Real-World Data Confirms Proximal Complement Inhibition in PNH
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
EASL 2026 Forum: Enhancing Patient-Clinician Communication
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
Desmopressin Dosing Refined for Central Diabetes Insipidus
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
Lupus Management: Progress and Persistent Challenges at EULAR 2026
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
EASL 2026: Alcohol Policy Action Needed for Liver Disease
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
Epithelial Dysfunction: A Unified Target in Airway Disease Management
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
Caplacizumab Improves iTTP Outcomes in Real-World Settings
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
Early Breast Cancer at ASCO 2026: Trials to Watch
Pediatric Advanced Bronchoscopy: Precision in Airway Management
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
CLL First-Line Therapy: Case-Based Insights from EHA 2026
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
Multidisciplinary Care Improves Spondyloarthritis Outcomes
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
More Breast Cancer Patients Can Skip Axillary Dissection
Infection Prevention Critical in Hematological Malignancies
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
Sarcoidosis: Current Understanding of Diagnosis and Management
AI in Oncology: Practical Applications Transforming Cancer Care
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
ILD Diagnosis and Management: A Practical ATS 2026 Update
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
Inluriyo™ and Verzenio® Presentations at ASCO 2026
RA Care: Navigating Treatment Choices at EULAR 2026
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
Ventilator Management: Foundations for Bedside Implementation
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
XLH Management: Rheumatology Must Adapt at EULAR 2026
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
NDMM Treatment Optimisation: Communication Key to Individualisation
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
Obesity Management Improves Psoriatic Disease Outcomes
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
ICI Dissemination Challenges Highlighted at ASCO 2026
Infection Prevention Critical in Hematological Malignancies
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
Evolving Infection Prevention in HSCT and Cellular Therapies
CD20-Targeted Therapies Remain Central to NHL Management
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
Multidisciplinary Approach Improves Autoimmune ILD Management
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
Early Intervention in SLE/LN Reduces Long-Term Damage
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
Hypercortisolism: Emerging Diagnostic and Management Insights
Triple Therapy Optimises COPD Outcomes at ATS 2026
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
ASCO 2026: Anticipating Advances in Oncology Treatment
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
How Immunotherapy Unmasks Invisible Lung Cancer
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
EASL 2026: PSC Therapies Advance Beyond Symptom Management
Inflammation Drives Sickle Cell Disease Pathophysiology
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
RA Treatment Optimisation: Applying Two Decades of Progress
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
EULAR 2026: Psoriatic Disease Spectrum Highlights
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
Afirma Molecular Testing: Unique Situations and New Prognostic Development
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
AI Foundation Models Enhance Diagnostic Insights in Oncology
ITP Management: Bridging Clinician and Patient Perspectives
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
Pediatric Pulmonary Research Gaps Highlighted for Global Health
ATS 2026: Ultrasound Education Advances for Clinical Practice
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
Outsmarting Shape-Shifting Lung Cancer Resistance
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
New Biologic Offers Option for Severe Eosinophilic Asthma
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
CAR T: Speed and Reliability Critical for Patient Outcomes
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
Low Alkaline Phosphatase: Recognizing Clinical Consequences
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
Macrophages: Dual Role in Haematological Malignancies Explored
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
Novel Biomarkers Improve Pediatric Solid Tumor Detection
EHA 2026: Anticipating Advances in Haematological Malignancies
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
CML Survivorship: Beyond Survival to Quality of Life
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
Classic CAH: New Approaches to Glucocorticoid Dosing
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
Immunological Insights Inform ILD & Transplant Outcomes
Real-World Data Confirms Proximal Complement Inhibition in PNH
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
EASL 2026 Forum: Enhancing Patient-Clinician Communication
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
Desmopressin Dosing Refined for Central Diabetes Insipidus
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
Lupus Management: Progress and Persistent Challenges at EULAR 2026
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
EASL 2026: Alcohol Policy Action Needed for Liver Disease
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
Epithelial Dysfunction: A Unified Target in Airway Disease Management
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
